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Summary Background. The first UK guidelines for the management of hidradenitis suppura-
tiva (HS) were published by the British Association of Dermatologists (BAD) in
2018. The guidelines contained a set of audit criteria.
Aim. To evaluate current HS management against the audit standards in the BAD
guidelines.
Methods. BAD members were invited to complete audit questionnaires between
January and May 2020 for five consecutive patients with HS per department.
Results. In total, 88 centres participated, providing data for 406 patients. Disease
staging using the Hurley system and disease severity using a validated tool during
follow-ups was documented in 75% and 56% of cases, respectively, while quality of
life and pain were documented in 49% and 50% of cases, respectively. Screening for
cardiovascular disease risk factors was as follows: smoking 75%, body mass index
27% and others such as lipids and diabetes 57%. Screening for depression and anxi-
ety was performed in 40% and 25% of cases, respectively. Support for smokers or
obese patients was documented in 35% and 23% of cases. In total, 182 patients
were on adalimumab, of whom 68% had documentation of baseline disease severity,
and 76% were reported as having inadequate response or contraindications to sys-
temic treatments; 44% of patients continued on adalimumab despite having < 25%
improvement in lesion count.
Conclusion. UK dermatologists performed well against several audit standards,
including documenting disease staging at baseline and smoking status. However,
improvements are needed, particularly with regard to screening and management of
comorbidities that could reduce the long-term complications associated with HS. A
re-audit is required to evaluate changes in practice in the future.
Introduction
Hidradenitis suppurativa (HS) is a painful, chronic,
suppurative skin condition with a relapsing and remit-
ting course that mostly affects the intertriginous areas.
The global prevalence of HS is around 1%. It affects
females more commonly than males in Europe and
North America, with a ratio of 3 : 1, and typically
begins in the second or third decade of life.1,2 HS is
associated with substantial morbidity due to pain and
scarring.3
In 2018, the British Association of Dermatologists
(BAD) published the first UK guidelines for the man-
agement of HS.4 The initial management in mild-to-
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moderate HS includes a topical antiseptic and oral
tetracyclines. The second-line treatment is a combina-
tion of clindamycin and rifampicin for 10–12 weeks. If
there is an inadequate response, the next lines of ther-
apy are dapsone or acitretin [the latter reserved for
males and nonfertile (due to infertility, age, contracep-
tion use) females]. In case of treatment failure with
two or more systemic therapies, or the presence of
contraindications, the patient may proceed to biologic
therapy with weekly adalimumab injections.
The guidelines have several recommendations for
more comprehensive management of people with HS
and audit criteria were established. All people with HS
must be provided with a patient information leaflet
(PIL) available on the BAD website (www.bad.org.uk/
leaflets). Hurley staging and the disease severity at base-
line, quality of life (QoL) and pain measurement using
validated instruments such as the Dermatology Life
Quality Index (DLQI), Pain Numeric Rating Scale (Pain-
NRS) or Pain Visual Analogue Scale (Pain-VAS) should
be documented at each visit. Additionally, at each clinic
visit, smoking status and body mass index (BMI) should
be assessed. Counselling and education should be
offered to all smokers and those with BMI ≥ 35 kg/m2.
Screening for mental health problems and cardiovascu-
lar disease (CVD) risk factors should be undertaken
annually to identify at-risk patients as per guidelines.
When commencing adalimumab, baseline lesion
count and Hurley staging must be documented. At
12 weeks, an improvement of < 25% in the lesion
count or an increase in draining sinuses or abscesses
should warrant discontinuation of adalimumab. Those
undergoing surgery need to be aware of the long
recovery time postoperatively, and it is necessary that
all patients have a preoperative discussion with their
clinicians to manage expectations appropriately.
Our audit aims to assess the current clinical prac-
tices in these areas against the audit standards set in
the guidelines.
Methods
We invited all members of the BAD to participate in a
national audit between January and May 2020. Each
participant was requested to collect the data from five
consecutive people with HS per department, covering
the work of ≥ 1 clinician, under follow-up in their
department for a minimum of 12 months. All data
were obtained from respondents using an Excel (Micro-
soft Corp., Redmond, CA, USA) spreadsheet proforma
returned to the BAD by email. No patient-identifiable
data were requested.
Statistical analysis
Initial data extraction was conducted using a novel
and reproducible program written in the R statistical
language (V3.6_ and the readxl package). The code
and a blank example of the questionnaire can be
found at https://github.com/sps41/HSaudit (https://
doi.org/10.5281/zenodo.3885305). Code is freely
usable under a Massachusetts Institute of Technology




We received responses from 82 BAD members cover-
ing 88 hospitals across the UK (Fig. 1). Data from 406
patients were included in the final data analysis.
Documentation
The results showed that 41% of cases had documenta-
tion of receiving a PIL. There was documentation of
Hurley staging at baseline in 75% of cases, and disease
severity using a validated tool in 56%. QoL and pain
were documented in 49% and 50% of cases, respec-
tively (Fig. 2).
Figure 1 Map of the UK showing the locations of the 82 audited
centres.
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Risk factors
Smoking status was documented in 75% of cases, and
35% of those identified as smokers were offered a refer-
ral to a smoking cessation service. Almost half of
patients had their weight recorded, and 27% had their
BMI documented. Of those with a BMI ≥ 35 kg/m2,
23% were referred to a dietician (Fig. 3). Our data
showed that screening for depression and anxiety was
documented in 40% and 25% of cases, respectively.
Screening for risk factors for CVD was recorded in
57% (Fig. 4).
Adalimumab
Of the 182 patients who were on adalimumab ther-
apy, 77% and 68% had documentation of baseline
lesion count and Hurley staging, respectively, while
76% had any contraindications to or failure to
respond to conventional therapy noted. For 44%, there
was documentation of stopping treatment when there
was a reduction of ≥ 25% in inflammatory nodule and
abscess lesion count. The data show that approxi-
mately one-third (30%) of patients underwent surgical
intervention, of whom the majority had documenta-
tion of presurgical discussion (74%).
Discussion
Our audit revealed there are areas where documenta-
tion was done well, ≥ 70% cases, covering baseline
disease severity, smoking status and baseline docu-
mentation prior to starting adalimumab therapy.
Other areas require improvement, especially in refer-
ring smokers and those with BMI ≥ 35 kg/m2 to
appropriate services, and in screening for anxiety;
these aspects of holistic care were documented in
< 40% of patients.
In many cases, people with HS spend years before
getting a correct diagnosis and being seen by a special-
ist.6 With the plethora of misinformation about the
disease, it is important for those with HS to have reli-
able sources of information to better understand the
condition. The results show that there was insufficient
documentation of the provision of a PIL (41%). Classi-
fying disease at baseline as mild, moderate or severe
based on the Hurley system assists in triaging and
management decisions, and it was encouraging that
most patients had documentation of the Hurley stag-
ing at baseline (75%). The burden of HS on QoL is
often substantial, and pain is the most influential
symptom affecting QoL.7 Assessment of disease severity
using validated instruments was performed in almost
half of cases.
Smokers are twice as likely to develop HS,8 and they
may have more severe disease compared with non-
smokers.9 Smoking status was documented in most
cases but only one-third of those requiring smoking
cessation support received a referral. There is as yet
no definitive evidence to confirm that quitting smoking
attenuates disease severity9 but nonsmokers appear to
have a better response to medical therapy compared
with smokers.10
People with HS have an increased risk of developing
major adverse cardiovascular events [incidence rate
ratio (IRR) = 1.53] and increased mortality
(IRR = 1.35).11 There is a known association between
HS and metabolic syndrome.12 These data make a
compelling case to screen people with HS for risk fac-
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Figure 2 Percentage of audited patients
for whom there was documentation of
(1) baseline disease stage using the Hur-
ley system, (2) disease severity using a
recognized instrument, (3) quality of life,
and (4) pain.
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referral to weight management services. Screening for
diabetes and hyperlipidaemia was performed in 57%.
HS is a painful disease and has a profound impact on
mental health with an increased risk of suicide.13,14
The guidelines recommend annual screening for men-
tal health disease, and in our audit, only 40% and
25% were screened for depression and anxiety, respec-
tively. All these factors are inter-related and emphasize
the importance of a holistic approach in managing
people with HS.
In our audit, 46% were on adalimumab. The nodule
count and Hurley staging were documented in two-
thirds of cases. Of note, 44% remained on adalimumab
despite having a suboptimal response based on the
guideline recommendations. It may be that adjuvant
therapy was introduced in the first instance to regain
disease control, rather than discontinuing adali-
mumab, in the context that other biologic therapy
options are difficult to access (and may not be funded)
for HS in the UK.
In terms of study limitations, the results of the audit
may have been influenced by self-auditing, which
would introduce bias. Additionally, the audit data may
reflect a lack of documentation, rather than true prac-
tice.
Our national audit was performed relatively soon
after the publication of the first UK guidelines for
managing people with HS, and the results demonstrate
substantial variation in adherence to the audit criteria;
therefore, this should serve as a baseline performance
for future re-audits. There are areas such as docu-
menting Hurley staging in which UK dermatologists
are performing well, but there is a need for improve-
ment in several aspects such as screening for CVD risk
factors and mental health problems. Implementing the
guidelines recommendations may be impeded by the
lack of resources and supporting services in some
areas and more recently by the move towards virtual
consultations during the COVID-19 outbreak. We sug-
gest that clinicians use an HS proforma to ensure that
the data required are collected routinely at each
patient appointment. Our other recommendations are
to: (i) use a standardized data collection form in the
clinic and annual proformas to screen for CVD risk
factors, depression and anxiety; (ii) engage with local
resources for lifestyle modification (i.e. smoking cessa-
tion and weight loss); (iii) set up HS multidisciplinary
clinics for local integration between dermatology, HS
surgery and wound-healing services; and (iv) re-audit
in 5 years to evaluate changes in practice.
Conclusion
The BAD HS guidelines were intended to encourage
best practice and reduce inequalities in HS care across
the UK. The audit results show that clinicians are
already performing relatively well in some areas but
improvements are needed, particularly with regard to
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Figure 3 Percentage of audited patients
for whom documentation was available
for (1) smoking status, (2) referral to
smoking cessation service if relevant,
(3) body weight, (4) BMI, and (5) referral





Figure 4 Percentage of audited patients for whom there was doc-
umentation of (1) screening for depression, (2) screening for anx-
iety and (3) screening for cardiovascular risk factors.
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reduce the long-term complications associated with
HS. As always, a re-audit is needed to determine
whether the guidelines and associated audit criteria
are able to drive up standards in the management of
people with HS.
What’s already known about this topic?
• The first UK guidelines for HS were published
in 2018 and contain a set of audit standards
against which to compare current HS manage-
ment.
What does this study add?
• Some audit standards, including baseline HS
staging and documentation of smoking status,
were met relatively well.
• However, documentation of BMI and referral to
weight management services, screening for men-
tal health problems and discontinuation of adali-
mumab if there was insufficient response were
adhered to less well.
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